Semnur Pharmaceuticals, Inc., a late-stage biopharmaceutical company developing non-opioid pain product SP-102/SEMDEXA, reports sharply higher operating expenses and losses for the quarter and six months ended June 30, 2026. Research and development and general and administrative spending rose significantly as the company advances Phase 3 development.
For the six-month period, the company recorded a net loss of $8.9 million, compared with $1.7 million a year earlier, driven by higher R&D, stock-based compensation and corporate costs. Cash and cash equivalents were only $39 thousand against total liabilities of $31.6 million, resulting in a stockholders’ deficit of $29.7 million and a heavy reliance on related-party funding from parent Scilex.
Management explicitly states that recurring losses, minimal cash, dependence on external financing and Scilex support, and the need to fund continued development of SP-102 raise substantial doubt about the ability to continue as a going concern. Previously announced equity financings, including a $20 million PIPE and a $100 million Bitcoin-funded purchase agreement, were terminated. After quarter end, the company signed a binding term sheet with iHolding Group LLP for a proposed $100 million common stock investment, but closing is subject to numerous conditions and may not occur.
Semnur Pharmaceuticals, Inc. is registering the resale of up to 203,737,349 shares of its Common Stock and the issuance of up to 7,432,122 shares upon the exercise of up to 510,000 warrants. The prospectus supplement updates the Form S-1 and states the company will not receive proceeds from the resale of those Resale Shares but will receive proceeds from any warrant exercises.
The company also disclosed a binding term sheet with iHolding Group LLP for a proposed $100,000,000 investment at $10.00 per share (approximately 10,000,000 shares), subject to due diligence, board and stockholder approvals, definitive agreements and customary closing conditions. The supplement notes last reported trading prices of Common Stock at $0.78 per share and Public Warrants at $0.04 per warrant on July 6, 2026.
Semnur Pharmaceuticals entered into a binding term sheet with iHolding Group LLP for a proposed $100,000,000 equity investment. iHolding is expected to buy newly issued Semnur common shares at $10.00 per share, or about 10,000,000 shares, pending detailed agreements and approvals.
The companies expect proceeds, if the deal closes, to support Semnur’s pipeline, including the ongoing Phase 3 program for SEMDEXA (SP-102), and broader growth initiatives. The transaction is subject to due diligence, definitive agreements, board, stockholder and regulatory approvals, and may not be completed.